Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,739.39 | 71.87 | -0.92% |
| DAX 40 | 25,046.36 | 325.39 | -1.28% |
| Dow JONES (US) | 52,111.21 | 756.77 | -1.43% |
| FTSE 100 | 10,639.26 | 85.77 | -0.80% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 25,982.68 | 26.18 | -0.10% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,623.48 | 39.95 | -0.52% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |